Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma

Cancer Research

Volumn 68, Issue 23, 2008, Pages 9884-9891

  Saenger, Yvonne M ^a   Li, Yanyun ^a   Chiou, Karoline C ^a   Chan, Brian ^d   Rizzuto, Gabrielle ^a   Terzulli, Stephanie L ^a   Merghoub, Taha ^a   Houghton, Alan N ^a,b,c   Wolchok, Jedd D ^a,b,c  

^a Immunology Program   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d SUNY Downstate Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; FC RECEPTOR; GAMMA INTERFERON; GLYCOPROTEIN GP 100; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TA99; MONOPHENOL MONOOXYGENASE; PLASMID DNA; TYROSINASE ANTIBODY; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; ENZYME LINKED IMMUNOSPOT ASSAY; EXPRESSION VECTOR; FEMALE; GENE GUN IMMUNIZATION; GENE LOCUS; GENETIC CODE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LUNG NODULE; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TUMOR GROWTH; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DNA; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OXIDOREDUCTASES; RECEPTORS, FC; VACCINES, DNA;

EID: 57149110636     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2233     Document Type: Article

References (39)

1. Uchi H, Stan R, Turk MJ, et al. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol 2006;90:215-41.
2. Drake CG, Jaffee E, Pardoll DM.Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81.
3. Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005;175:6169-76.
4. Orlandi F, Venanzi FM, Concetti A, et al. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. Clin Cancer Res 2007;13:6195-203.
5. Harbers SO, Crocker A, Catalano G, et al. Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 2007;117:1361-9.
6. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34-47.
7. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002;110:71-9.
8. Kim PS, Armstrong TD, Song H, et al. Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J Clin Invest 2008;118:1700-11.
9. Wolpoe ME, Lutz ER, Ercolini AM, et al. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J Immunol 2003;171:2161-9.
10. Houghton AN. The serological analysis of human cancer. Identification of differentiation antigens on melanoma and melanocytes. Prog Clin Biol Res 1983;119:199-205.
11. Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995;182:1609-14.
12. Guevara-Patino JA, Engelhorn ME, Turk MJ, et al. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest 2006;116:1382-90.
13. Gold JS, Ferrone CR, Guevara-Patino JA, et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 2003;170:5188-94.
14. Schreurs MW, de Boer AJ, Figdor CG, Adema GJ. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res 1998;58:2509-14.
15. Taylor C, Hershman D, Shah N, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007;13:5133-43.
16. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR γ chain deletion results in pleiotrophic effector cell defects. Cell 1994;76:519-29.
17. Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998;188:277-86.
18. Kievits F, Ivanyi P. Monomorphic anti-HLA monoclonal antibody (W6/32) recognizes polymorphic H-2 heavy-chain determinants exposed by association with bovine or human but not murine β 2-microglobulin. Hum Immunol 1987;20:115-26.
19. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006;313:670-3.
20. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008;320:373-6.
21. Engelhorn ME, Guevara-Patino JA, Merghoub T, et al. Mechanisms of immunization against cancer using chimeric antigens. Mol Ther 2008;16:773-81.
22. Dyall R, Bowne WB, Weber LW, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998;188:1553-61.
23. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A 1998;95:652-6.
24. Trcka J, Moroi Y, Clynes RA, et al. Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity 2002;16:861-8.
25. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005;310:1510-2.
26. Carroll MC. The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol 1998;16:545-68.
27. Kahl B. Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma. Semin Hematol 2008;45:90-4.
28. Vijayasaradhi S, Houghton AN. Purification of an autoantigenic 75-kDa human melanosomal glycoprotein. Int J Cancer 1991;47:298-303.
29. Banerjee D, Matthews P, Matayeva E, Kaufman JL, Steinman RM, Dhodapkar KM. Enhanced T-cell responses to glioma cells coated with the anti-EGF receptor antibody and targeted to activating FcγRs on human dendritic cells. J Immunother 2008;31:113-20.
30. Garrido G, Lorenzano P, Sanchez B, et al. T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. Cancer Immunol Immunother 2007;56:1701-10.
31. Wang H, Wang D, Li M, et al. Enhanced anti-tumor immunity generated by Rituximab-coated tumor cell vaccine. Cancer Lett 2008;268:129-36.
32. Chakraborty M, Gelbard A, Carrasquillo JA, et al. Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer Immunol Immunother 2008;57:1173-83.
33. Takechi Y, Hara I, Naftzger C, Xu Y, Houghton AN. A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res 1996;2:1837-42.
34. Bevaart L, Jansen MJ, van Vugt MJ, Verbeek JS, van de Winkel JG, Leusen JH. The high-affinity IgG receptor, FcγRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res 2006;66:1261-4.
35. Getahun A, Dahlstrom J, Wernersson S, Heyman B. IgG2a-mediated enhancement of antibody and T cell responses and its relation to inhibitory and activating Fc γ receptors. J Immunol 2004;172:5269-76.
36. Weber LW, Bowne WB, Wolchok JD, et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998;102:1258-64.
37. Bowne WB, Srinivasan R, Wolchok JD, et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999;190:1717-22.
38. Patel D, Balderes P, Lahiji A, et al. Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1. Hum Antibodies 2007;16:127-36.
39. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5.